Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,170

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis

Nahid, Payam, Dorman, Susan E., Alipanah, Narges, Barry, Pennan M., Brozek, Jan L., Cattamanchi, Adithya, Chaisson, Lelia H., Chaisson, Richard E., Daley, Charles L., Grzemska, Malgosia, Higashi, Julie M., Ho, Christine S., Hopewell, Philip C., Keshavjee, Salmaan A., Lienhardt, Christian, Menzies, Richard, Merrifield, Cynthia, Narita, Masahiro, O'Brien, Rick, Peloquin, Charles A., Raftery, Ann, Saukkonen, Jussi, Schaaf, H. Simon, Sotgiu, Giovanni, Starke, Jeffrey R., Migliori, Giovanni Battista, Vernon, Andrew·2016·Clinical Infectious Diseases
DOI 10.1093/cid/ciw376
Open this paper in CoChat — free account

Abstract

The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America jointly sponsored the development of this guideline for the treatment of drug-susceptible tuberculosis, which is also endorsed by the European Respiratory Society and the US National Tuberculosis Controllers Association. Representatives from the American Academy of Pediatrics, the Canadian Thoracic Society, the International Union Against Tuberculosis and Lung Disease, and the World Health Organization also participated in the development of the guideline. This guideline provides recommendations on the clinical and public health management of tuberculosis in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis. For all recommendations, literature reviews were performed, followed by discussion by an expert committee according to the Grading of Recommendations, Assessment, Development and Evaluation methodology. Given the public health implications of prompt diagnosis and effective management of tuberculosis, empiric multidrug treatment is initiated in almost all situations in which active tuberculosis is suspected. Additional characteristics such as presence of comorbidities, severity of disease, and response to treatment influence management decisions. Specific recommendations on the use of case management strategies (including directly observed therapy), regimen and dosing selection in adults and children (daily vs intermittent), treatment of tuberculosis in the presence of HIV infection (duration of tuberculosis treatment and timing of initiation of antiretroviral therapy), as well as treatment of extrapulmonary disease (central nervous system, pericardial among other sites) are provided. The development of more potent and better-tolerated drug regimens, optimization of drug exposure for the component drugs, optimal management of tuberculosis in special populations, identification of accurate biomarkers of treatment effect, and the assessment of new strategies for implementing regimens in the field remain key priority areas for research. See the full-text online version of the document for detailed discussion of the management of tuberculosis and recommendations for practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciw376

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 506

  1. Fox, 1999, Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications, Int J Tuberc Lung Dis, 3, S231
  2. Mitchison, 2012, The chemotherapy of tuberculosis: past, present and future, Int J Tuberc Lung Dis, 16, 724, 10.5588/ijtld.12.0083 · DOI
  3. Gillespie, 2014, Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis, N Engl J Med, 371, 1577, 10.1056/NEJMoa1407426 · DOI · Paper page
  4. Zierski, 1980, Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study, Tubercle, 61, 41, 10.1016/0041-3879(80)90060-4 · DOI
  5. Phillips, 2013, An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse, PLoS One, 8, e63840, 10.1371/journal.pone.0063840 · DOI
  6. Aber, 1978, Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy [in French], Bull Int Union Tuberc, 53, 276
  7. Benator, 2002, Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial, Lancet, 360, 528, 10.1016/S0140-6736(02)09742-8 · DOI · Paper page
  8. Menzies, 2014, Treatment of tuberculosis disease. Canadian Tuberculosis Standards
  9. Weiner, 2003, Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine, Am J Respir Crit Care Med, 167, 1341, 10.1164/rccm.200208-951OC · DOI
  10. Essential components of a tuberculosis prevention and control program, 1995, Recommendations of the Advisory Council for the Elimination of Tuberculosis, MMWR Recomm Rep, 44, 1
  11. Taylor, 2005, Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America, MMWR Recomm Rep, 54, 1
  12. Hopewell, 2006, International standards for tuberculosis care, Lancet Infect Dis, 6, 710, 10.1016/S1473-3099(06)70628-4 · DOI · Paper page
  13. Migliori, 2012, European Union standards for tuberculosis care, Eur Respir J, 39, 807, 10.1183/09031936.00203811 · DOI
  14. Hopewell, 2014, Updating the International Standards for Tuberculosis Care. Entering the era of molecular diagnostics, Ann Am Thorac Soc, 11, 277, 10.1513/AnnalsATS.201401-004AR · DOI
  15. Tahan, 2002, A ten-step process to develop case management plans, Lippincotts Case Manag, 7, 231, 10.1097/00129234-200211000-00005 · DOI
  16. Garner, 2007, Promoting adherence to tuberculosis treatment, Bull World Health Organ, 85, 404, 10.2471/BLT.06.035568 · DOI
  17. Clark, 2007, Effect of pharmacist-led patient education on adherence to tuberculosis treatment, Am J Health Syst Pharm, 64, 497, 10.2146/ajhp050543 · DOI
  18. Liefooghe, 1999, A randomised trial of the impact of counselling on treatment adherence of tuberculosis patients in Sialkot, Pakistan, Int J Tuberc Lung Dis, 3, 1073
  19. M'Imunya, 2012, Patient education and counselling for promoting adherence to treatment for tuberculosis, Cochrane Database Syst Rev, 5, CD006591
  20. Flores, 2005, The impact of medical interpreter services on the quality of health care: a systematic review, Med Care Res Rev, 62, 255, 10.1177/1077558705275416 · DOI
  21. Krishnaswami, 1981, A randomised study of two policies for managing default in out-patients collecting supplies of drugs for pulmonary tuberculosis in a large city in South India, Tubercle, 62, 103, 10.1016/0041-3879(81)90017-9 · DOI
  22. Kunawararak, 2011, Tuberculosis treatment with mobile-phone medication reminders in northern Thailand, Southeast Asian J Trop Med Public Health, 42, 1444
  23. Tanke, 1994, Automated telephone reminders in tuberculosis care, Med Care, 32, 380, 10.1097/00005650-199404000-00006 · DOI
  24. Liu, 2014, Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment, Cochrane Database Syst Rev, 11, CD006594
  25. Iribarren, 2013, TextTB: a mixed method pilot study evaluating acceptance, feasibility, and exploring initial efficacy of a text messaging intervention to support TB treatment adherence, Tuberc Res Treat, 2013, 349394
  26. Lutge, 2012, Material incentives and enablers in the management of tuberculosis, Cochrane Database Syst Rev, 1, CD007952
  27. Martins, 2009, Food incentives to improve completion of tuberculosis treatment: randomised controlled trial in Dili, Timor-Leste, BMJ, 339, b4248, 10.1136/bmj.b4248 · DOI
  28. Wright, 2015, Community-based directly observed therapy (DOT) versus clinic DOT for tuberculosis: a systematic review and meta-analysis of comparative effectiveness, BMC Infect Dis, 15, 210, 10.1186/s12879-015-0945-5 · DOI
  29. Chaulk, 1998, Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel, JAMA, 279, 943, 10.1001/jama.279.12.943 · DOI · Paper page
  30. Liu, 2005, DOT and timely treatment completion among Asian-born immigrant tuberculosis patients, Int J Tuberc Lung Dis, 9, 884
  31. Menzies, 2009, Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis, PLoS Med, 6, e1000146, 10.1371/journal.pmed.1000146 · DOI
  32. Menzies, 2009, Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis, PLoS Med, 6, e1000150, 10.1371/journal.pmed.1000150 · DOI
  33. LoBue, 2005, Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993–2002, Int J Tuberc Lung Dis, 9, 501
  34. Hoopes, 2008, Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003, Arch Intern Med, 168, 1984, 10.1001/archinte.168.18.1984 · DOI
  35. Jenkins, 2011, Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994–2009, PLoS One, 6, e22927, 10.1371/journal.pone.0022927 · DOI
  36. Yuen, 2015, Global and regional burden of isoniazid-resistant tuberculosis, Pediatrics, 136, e50, 10.1542/peds.2015-0172 · DOI
  37. Snider, 1980, Pyridoxine supplementation during isoniazid therapy, Tubercle, 61, 191, 10.1016/0041-3879(80)90038-0 · DOI
  38. Visser, 2004, The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis, Int J Tuberc Lung Dis, 8, 260
  39. Mitchison, 1993, Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months, Am Rev Respir Dis, 147, 1062, 10.1164/ajrccm/147.4.1062 · DOI
  40. Jo, 2014, Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen, Respir Med, 108, 654, 10.1016/j.rmed.2014.01.010 · DOI
  41. Horne, 2010, Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis, Lancet Infect Dis, 10, 387, 10.1016/S1473-3099(10)70071-2 · DOI · Paper page
  42. Chang, 2004, A nested case-control study on treatment-related risk factors for early relapse of tuberculosis, Am J Respir Crit Care Med, 170, 1124, 10.1164/rccm.200407-905OC · DOI
  43. Khan, 2006, Lack of weight gain and relapse risk in a large tuberculosis treatment trial, Am J Respir Crit Care Med, 174, 344, 10.1164/rccm.200511-1834OC · DOI
  44. Baker, 2011, The impact of diabetes on tuberculosis treatment outcomes: a systematic review, BMC Med, 9, 81, 10.1186/1741-7015-9-81 · DOI · Paper page
  45. Wang, 2015, Optimal duration of anti-TB treatment in patients with diabetes: nine or six months?, Chest, 147, 520, 10.1378/chest.14-0918 · DOI
  46. Leung, 2015, Smoking adversely affects treatment response, outcome and relapse in tuberculosis, Eur Respir J, 45, 738, 10.1183/09031936.00114214 · DOI
  47. Ahmad Khan, 2012, An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection, Clin Infect Dis, 55, 1154, 10.1093/cid/cis630 · DOI
  48. Centers for Disease Control and Prevention, 2013, Core curriculum on tuberculosis: what the clinician should know.
  49. Lin, 2010, Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis, Int J Tuberc Lung Dis, 14, 806
  50. Navarro, 2006, Drug-related hepatotoxicity, N Engl J Med, 354, 731, 10.1056/NEJMra052270 · DOI · Paper page
  51. Saukkonen, 2006, An official ATS statement: hepatotoxicity of antituberculosis therapy, Am J Respir Crit Care Med, 174, 935, 10.1164/rccm.200510-1666ST · DOI · Paper page
  52. Sharma, 2010, Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity, Clin Infect Dis, 50, 833, 10.1086/650576 · DOI
  53. Chang, 2010, The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate, Clin Infect Dis, 51, 366, 10.1086/654806 · DOI
  54. Vernon, 1999, Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium, Lancet, 353, 1843, 10.1016/S0140-6736(98)11467-8 · DOI · Paper page
  55. Burman, 2006, Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis, Am J Respir Crit Care Med, 173, 350, 10.1164/rccm.200503-417OC · DOI
  56. Weiner, 2005, Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis, Clin Infect Dis, 40, 1481, 10.1086/429321 · DOI
  57. Narendran, 2014, Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy, Clin Infect Dis, 59, 1798, 10.1093/cid/ciu674 · DOI
  58. Nunn, 2008, Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial, BMJ, 337, a257, 10.1136/bmj.a257 · DOI
  59. Suthar, 2012, Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis, Bull World Health Organ, 90, 128C, 10.2471/BLT.11.093260 · DOI
  60. Wiktor, 1999, Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial, Lancet, 353, 1469, 10.1016/S0140-6736(99)03465-0 · DOI · Paper page
  61. Masur, 2014, Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America, Clin Infect Dis, 58, 1308, 10.1093/cid/ciu094 · DOI · Paper page
  62. Luetkemeyer, 2014, Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs, J Acquir Immune Defic Syndr, 65, 423, 10.1097/QAI.0000000000000030 · DOI
  63. Meintjes, 2008, Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings, Lancet Infect Dis, 8, 516, 10.1016/S1473-3099(08)70184-1 · DOI · Paper page
  64. Meintjes, 2010, Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome, AIDS, 24, 2381, 10.1097/QAD.0b013e32833dfc68 · DOI · Paper page
  65. Strang, 1987, Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei, Lancet, 2, 1418, 10.1016/S0140-6736(87)91127-5 · DOI
  66. Strang, 1988, Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei, Lancet, 2, 759, 10.1016/S0140-6736(88)92415-4 · DOI
  67. Hakim, 2000, Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients, Heart, 84, 183, 10.1136/heart.84.2.183 · DOI
  68. Mayosi, 2014, Immunotherapy for tuberculous pericarditis, N Engl J Med, 371, 2534
  69. Reuter, 2006, Experience with adjunctive corticosteroids in managing tuberculous pericarditis, Cardiovasc J S Afr, 17, 233
  70. Chaisson, 2014, Immunotherapy for tuberculous pericarditis, N Engl J Med, 371, 2535, 10.1056/NEJMe1409356 · DOI
  71. Thwaites, 2009, British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children, J Infect, 59, 167, 10.1016/j.jinf.2009.06.011 · DOI · Paper page
  72. Ashby, 1955, Tuberculous meningitis treated with cortisone, Lancet, 268, 65, 10.1016/S0140-6736(55)90003-9 · DOI
  73. O'Toole, 1969, Dexamethasone in tuberculous meningitis. Relationship of cerebrospinal fluid effects to therapeutic efficacy, Ann Intern Med, 70, 39, 10.7326/0003-4819-70-1-39 · DOI
  74. Escobar, 1975, Mortality from tuberculous meningitis reduced by steroid therapy, Pediatrics, 56, 1050, 10.1542/peds.56.6.1050 · DOI
  75. Girgis, 1983, The use of dexamethasone in preventing ocular complications in tuberculous meningitis, Trans R Soc Trop Med Hyg, 77, 658, 10.1016/0035-9203(83)90195-5 · DOI
  76. Girgis, 1991, Dexamethasone adjunctive treatment for tuberculous meningitis, Pediatr Infect Dis J, 10, 179, 10.1097/00006454-199103000-00002 · DOI
  77. Kumarvelu, 1994, Randomized controlled trial of dexamethasone in tuberculous meningitis, Tuber Lung Dis, 75, 203, 10.1016/0962-8479(94)90009-4 · DOI
  78. Chotmongkol, 1996, Corticosteroid in tuberculous meningitis, J Med Assoc Thai, 79, 83
  79. Dooley, 1997, Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature, Clin Infect Dis, 25, 872, 10.1086/515543 · DOI
  80. Schoeman, 1997, Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis, Pediatrics, 99, 226, 10.1542/peds.99.2.226 · DOI · Paper page
  81. Thwaites, 2004, Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults, N Engl J Med, 351, 1741, 10.1056/NEJMoa040573 · DOI · Paper page
  82. Prasad, 2008, Corticosteroids for managing tuberculous meningitis, Cochrane Database Syst Rev, CD002244
  83. Malhotra, 2009, Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with tuberculous meningitis, Ann Trop Med Parasitol, 103, 625, 10.1179/000349809X12502035776315 · DOI
  84. Critchley, 2013, Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis, Lancet Infect Dis, 13, 223, 10.1016/S1473-3099(12)70321-3 · DOI
  85. Ho, 2015, The impact of sputum quality on tuberculosis diagnosis: a systematic review, Int J Tuberc Lung Dis, 19, 537, 10.5588/ijtld.14.0798 · DOI
  86. Gordin, 1989, Presumptive diagnosis and treatment of pulmonary tuberculosis based on radiographic findings, Am Rev Respir Dis, 139, 1090, 10.1164/ajrccm/139.5.1090 · DOI
  87. American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America, 2003, Treatment of tuberculosis, MMWR Recomm Rep, 52, 1
  88. Zumla, 2013, Tuberculosis, N Engl J Med, 368, 745, 10.1056/NEJMra1200894 · DOI · Paper page
  89. D'Ambrosio, 2014, Tuberculosis elimination: theory and practice in Europe, Eur Respir J, 43, 1410, 10.1183/09031936.00198813 · DOI
  90. Lonnroth, 2015, Towards tuberculosis elimination: an action framework for low-incidence countries, Eur Respir J, 45, 928, 10.1183/09031936.00214014 · DOI · Paper page
  91. Zhang, 2003, The curious characteristics of pyrazinamide: a review, Int J Tuberc Lung Dis, 7, 6
  92. 1977, Tuberculosis in Tanzania: a follow-up of a national sampling survey of drug resistance and other factors, Tubercle, 58, 55, 10.1016/0041-3879(77)90032-0 · DOI
  93. Dharmadhikari, 2014, Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis, Int J Tuberc Lung Dis, 18, 1019, 10.5588/ijtld.13.0834 · DOI
  94. Fitzwater, 2010, Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy, Clin Infect Dis, 51, 371, 10.1086/655127 · DOI
  95. Telzak, 1997, Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis, Clin Infect Dis, 25, 666, 10.1086/513772 · DOI
  96. Long, 2003, Relative versus absolute noncontagiousness of respiratory tuberculosis on treatment, Infect Control Hosp Epidemiol, 24, 831, 10.1086/502145 · DOI
  97. Jindani, 1980, The early bactericidal activity of drugs in patients with pulmonary tuberculosis, Am Rev Respir Dis, 121, 939
  98. Jindani, 2003, Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days, Am J Respir Crit Care Med, 167, 1348, 10.1164/rccm.200210-1125OC · DOI · Paper page
  99. Diacon, 2014, The early bactericidal activity of antituberculosis drugs, Expert Rev Anti Infect Ther, 12, 223, 10.1586/14787210.2014.870884 · DOI
  100. Zumla, 2013, Advances in the development of new tuberculosis drugs and treatment regimens, Nat Rev Drug Discov, 12, 388, 10.1038/nrd4001 · DOI · Paper page
  101. Hu, 2000, Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide, J Bacteriol, 182, 6358, 10.1128/JB.182.22.6358-6365.2000 · DOI
  102. Gumbo, 2004, Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling, J Infect Dis, 190, 1642, 10.1086/424849 · DOI · Paper page
  103. Nuermberger, 2008, Using animal models to develop new treatments for tuberculosis, Semin Respir Crit Care Med, 29, 542, 10.1055/s-0028-1085705 · DOI
  104. Canetti, 1955, The tubercle bacillus in the pulmonary lesion of man; histobacteriology and its bearing on the therapy of pulmonary tuberculosis
  105. Russell, 2010, Tuberculosis: what we don't know can, and does, hurt us, Science, 328, 852, 10.1126/science.1184784 · DOI · Paper page
  106. Lenaerts, 2015, Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses, Immunol Rev, 264, 288, 10.1111/imr.12252 · DOI
  107. Dartois, 2014, The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells, Nat Rev Microbiol, 12, 159, 10.1038/nrmicro3200 · DOI · Paper page
  108. Kempker, 2015, Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis, Antimicrob Agents Chemother, 59, 3149, 10.1128/AAC.00379-15 · DOI
  109. Prideaux, 2011, High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions, Anal Chem, 83, 2112, 10.1021/ac1029049 · DOI · Paper page
  110. Prideaux, 2015, The association between sterilizing activity and drug distribution into tuberculosis lesions, Nat Med, 21, 1223, 10.1038/nm.3937 · DOI · Paper page
  111. Zhang, 2015, Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015, Int J Tuberc Lung Dis, 19, 1276, 10.5588/ijtld.15.0389 · DOI
  112. David, 1970, Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis, Appl Microbiol, 20, 810, 10.1128/am.20.5.810-814.1970 · DOI
  113. Vernon, 2004, In the treatment of tuberculosis, you get what you pay for, Am J Respir Crit Care Med, 170, 1040, 10.1164/rccm.2409005 · DOI
  114. Robinson, 2008, Patient-centered care and adherence: definitions and applications to improve outcomes, J Am Acad Nurse Pract, 20, 600, 10.1111/j.1745-7599.2008.00360.x · DOI · Paper page
  115. Gasner, 1999, The use of legal action in New York City to ensure treatment of tuberculosis, N Engl J Med, 340, 359, 10.1056/NEJM199902043400506 · DOI
  116. Pursnani, 2014, Risk factors for and outcomes of detention of patients with TB in New York City: an update: 2002–2009, Chest, 145, 95, 10.1378/chest.13-0324 · DOI
  117. Suwankeeree, 2014, Strategies to promote adherence to treatment by pulmonary tuberculosis patients: a systematic review, Int J Evid Based Healthc, 12, 3, 10.1097/01.XEB.0000444614.17658.46 · DOI
  118. Lienhardt, 2004, Tuberculosis control in resource-poor countries: have we reached the limits of the universal paradigm?, Trop Med Int Health, 9, 833, 10.1111/j.1365-3156.2004.01273.x · DOI
  119. Burman, 1997, Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment, Chest, 111, 1168, 10.1378/chest.111.5.1168 · DOI
  120. Mirsaeidi, 2015, Video directly observed therapy for treatment of tuberculosis is patient-oriented and cost-effective, Eur Respir J, 46, 871, 10.1183/09031936.00011015 · DOI
  121. Krueger, 2010, Videophone utilization as an alternative to directly observed therapy for tuberculosis, Int J Tuberc Lung Dis, 14, 779
  122. Hoffman, 2010, Mobile direct observation treatment for tuberculosis patients: a technical feasibility pilot using mobile phones in Nairobi, Kenya, Am J Prev Med, 39, 78, 10.1016/j.amepre.2010.02.018 · DOI
  123. Volmink, 2007, Directly observed therapy for treating tuberculosis, Cochrane Database Syst Rev, CD003343
  124. Pasipanodya, 2013, A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients, Clin Infect Dis, 57, 21, 10.1093/cid/cit167 · DOI
  125. Karumbi, 2015, Directly observed therapy for treating tuberculosis, Cochrane Database Syst Rev, 5, CD003343
  126. Moonan, 2011, Does directly observed therapy (DOT) reduce drug resistant tuberculosis?, BMC Public Health, 11, 19, 10.1186/1471-2458-11-19 · DOI
  127. King, 2010, Achieving international targets for tuberculosis treatment success among HIV-positive patients in New York City, Int J Tuberc Lung Dis, 14, 1613
  128. Kim, 2007, Treatment completion among TB patients returned to the community from a large urban jail, J Community Health, 32, 135, 10.1007/s10900-006-9036-2 · DOI
  129. Reis-Santos, 2015, Directly observed therapy of tuberculosis in Brazil: associated determinants and impact on treatment outcome, Int J Tuberc Lung Dis, 19, 1188, 10.5588/ijtld.14.0776 · DOI
  130. Cummings, 1998, Movement of tuberculosis patients and the failure to complete antituberculosis treatment, Am J Respir Crit Care Med, 157, 1249, 10.1164/ajrccm.157.4.9708058 · DOI
  131. Harlow, 1999, TB net tracking network provides continuity of care for mobile TB patients, Am J Public Health, 89, 1581, 10.2105/AJPH.89.10.1581 · DOI
  132. Centers for Disease Control and Prevention, 2008, Federal air travel restrictions for public health purposes—United States, June 2007-May 2008, MMWR Morb Mortal Wkly Rep, 57, 1009
  133. Centers for Disease Control and Prevention, 2012, Public health interventions involving travelers with tuberculosis—U.S. ports of entry, 2007–2012, MMWR Morb Mortal Wkly Rep, 61, 570
  134. van Hest, 2014, Tuberculosis control in big cities and urban risk groups in the European Union: a consensus statement, Euro Surveill, 19, 10.2807/1560-7917.ES2014.19.9.20728 · DOI
  135. Centers for Disease Control and Prevention, 2009, Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis, MMWR Morb Mortal Wkly Rep, 58, 7
  136. Boehme, 2011, Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study, Lancet, 377, 1495, 10.1016/S0140-6736(11)60438-8 · DOI · Paper page
  137. Flores, 2005, In-house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta-analysis and meta-regression, BMC Microbiol, 5, 55, 10.1186/1471-2180-5-55 · DOI
  138. Dinnes, 2007, A systematic review of rapid diagnostic tests for the detection of tuberculosis infection, Health Technol Assess, 11, 1, 10.3310/hta11030 · DOI · Paper page
  139. Gordin, 2000, Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group, JAMA, 283, 1445, 10.1001/jama.283.11.1445 · DOI · Paper page
  140. Centers for Disease Control and Prevention., 2011, Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection, MMWR Morb Mortal Wkly Rep, 60, 1650
  141. Getahun, 2015, Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries, Eur Respir J, 46, 1563, 10.1183/13993003.01245-2015 · DOI · Paper page
  142. 2000, Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement, Am J Respir Crit Care Med, 161, S221
  143. 1982, Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis, Bull World Health Organ, 60, 555
  144. Grzybowski, 1971, Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service, Am Rev Respir Dis, 104, 605
  145. Comstock, 1972, Preventive treatment of untreated, nonactive tuberculosis in an Eskimo population, Arch Environ Health, 25, 333, 10.1080/00039896.1972.10666182 · DOI
  146. Grzybows, 1966, Reactivations in inactive pulmonary tuberculosis, Am Rev Respir Dis, 93, 352
  147. Chang, 2006, Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis, Am J Respir Crit Care Med, 174, 1153, 10.1164/rccm.200605-637OC · DOI
  148. Sterling, 1999, Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons, AIDS, 13, 1899, 10.1097/00002030-199910010-00012 · DOI
  149. Tam, 1998, Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report, Am J Respir Crit Care Med, 157, 1726, 10.1164/ajrccm.157.6.9707037 · DOI
  150. Merle, 2014, A four-month gatifloxacin-containing regimen for treating tuberculosis, N Engl J Med, 371, 1588, 10.1056/NEJMoa1315817 · DOI
  151. Jindani, 2014, High-dose rifapentine with moxifloxacin for pulmonary tuberculosis, N Engl J Med, 371, 1599, 10.1056/NEJMoa1314210 · DOI
  152. Lienhardt, 2011, Operational research for improved tuberculosis control: the scope, the needs and the way forward, Int J Tuberc Lung Dis, 15, 6
  153. Cuevas, 2011, A multi-country non-inferiority cluster randomized trial of frontloaded smear microscopy for the diagnosis of pulmonary tuberculosis, PLoS Med, 8, e1000443, 10.1371/journal.pmed.1000443 · DOI
  154. Davis, 2013, Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis, Lancet Infect Dis, 13, 147, 10.1016/S1473-3099(12)70232-3 · DOI
  155. Diagnostic Standards and Classification of Tuberculosis in Adults and Children, 2000, This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999, Am J Respir Crit Care Med, 161, 1376
  156. 1991, A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council, Am Rev Respir Dis, 143, 262, 10.1164/ajrccm/143.2.262 · DOI
  157. Bock, 2002, A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment, Am J Respir Crit Care Med, 165, 1526, 10.1164/rccm.200201-047OC · DOI
  158. Zvada, 2010, Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers, Antimicrob Agents Chemother, 54, 3390, 10.1128/AAC.00345-10 · DOI
  159. Peloquin, 2007, Stability of antituberculosis drugs mixed in food, Clin Infect Dis, 45, 521, 10.1086/520011 · DOI
  160. Gallardo, 2016, Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis, Cochrane Database Syst Rev, 5, CD009913
  161. Monedero, 2011, Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: a review, Int J Tuberc Lung Dis, 15, 433, 10.5588/ijtld.09.0439 · DOI
  162. Albanna, 2013, Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis, Eur Respir J, 42, 721, 10.1183/09031936.00180612 · DOI
  163. Nunn, 2014, Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis, Int J Tuberc Lung Dis, 18, 1252, 10.5588/ijtld.14.0281 · DOI
  164. Lienhardt, 2011, Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial, JAMA, 305, 1415, 10.1001/jama.2011.436 · DOI
  165. Fish, 1997, The clinical pharmacokinetics of levofloxacin, Clin Pharmacokinet, 32, 101, 10.2165/00003088-199732020-00002 · DOI · Paper page
  166. Lehloenya, 2012, Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future, Expert Rev Anti Infect Ther, 10, 475, 10.1586/eri.12.13 · DOI
  167. Mehta, 1996, Rifampicin-induced immune thrombocytopenia, Tuber Lung Dis, 77, 558, 10.1016/S0962-8479(96)90056-8 · DOI
  168. Palmero, 2013, Difficult clinical management of anti-tuberculosis DRESS syndrome, Int J Tuberc Lung Dis, 17, 76, 10.5588/ijtld.12.0441 · DOI
  169. Bark, 2011, Clinical symptoms and microbiological outcomes in tuberculosis treatment trials, Tuberculosis (Edinb), 91, 601, 10.1016/j.tube.2011.05.007 · DOI
  170. Kiblawi, 1981, Fever response of patients on therapy for pulmonary tuberculosis, Am Rev Respir Dis, 123, 20
  171. Chien, 1998, Paradoxical reactions in HIV and pulmonary TB, Chest, 114, 933, 10.1378/chest.114.3.933 · DOI
  172. Bell, 2015, Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis, Int J Infect Dis, 32, 39, 10.1016/j.ijid.2014.12.030 · DOI
  173. Meintjes, 2009, Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy, Clin Chest Med, 30, 797, 10.1016/j.ccm.2009.08.013 · DOI
  174. Steele, 1991, Toxic hepatitis with isoniazid and rifampin. A meta-analysis, Chest, 99, 465, 10.1378/chest.99.2.465 · DOI · Paper page
  175. Tostmann, 2008, Antituberculosis drug-induced hepatotoxicity: concise up-to-date review, J Gastroenterol Hepatol, 23, 192, 10.1111/j.1440-1746.2007.05207.x · DOI · Paper page
  176. Ezer, 2013, Incidence of ethambutol-related visual impairment during treatment of active tuberculosis, Int J Tuberc Lung Dis, 17, 447, 10.5588/ijtld.11.0766 · DOI
  177. Chan, 2006, Ocular toxicity of ethambutol, Hong Kong Med J, 12, 56
  178. Talbert Estlin, 2010, Risk factors for ethambutol optic toxicity, Int Ophthalmol, 30, 63, 10.1007/s10792-009-9293-z · DOI
  179. Keeping, 1955, Optic neuritis following isoniazid therapy, Lancet, 269, 278, 10.1016/S0140-6736(55)92696-9 · DOI
  180. Cato, 1998, The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin, Clin Pharmacol Ther, 63, 414, 10.1016/S0009-9236(98)90036-4 · DOI
  181. Torseth, 1989, Evaluation of the antiviral effect of rifabutin in AIDS-related complex, J Infect Dis, 159, 1115, 10.1093/infdis/159.6.1115 · DOI
  182. Griffith, 1995, Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease, Clin Infect Dis, 21, 594, 10.1093/clinids/21.3.594 · DOI
  183. Weiner, 2005, Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis, Clin Infect Dis, 41, 1343, 10.1086/496980 · DOI
  184. Nix, 1989, Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin, Clin Pharmacol Ther, 46, 700, 10.1038/clpt.1989.207 · DOI
  185. Frost, 1992, Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin, Antimicrob Agents Chemother, 36, 830, 10.1128/AAC.36.4.830 · DOI
  186. Polk, 1989, Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers, Antimicrob Agents Chemother, 33, 1841, 10.1128/AAC.33.11.1841 · DOI
  187. Lehto, 1994, Effect of sucralfate on absorption of norfloxacin and ofloxacin, Antimicrob Agents Chemother, 38, 248, 10.1128/AAC.38.2.248 · DOI
  188. Sahai, 1993, Cations in the didanosine tablet reduce ciprofloxacin bioavailability, Clin Pharmacol Ther, 53, 292, 10.1038/clpt.1993.24 · DOI
  189. Lomaestro, 1993, Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin, Ann Pharmacother, 27, 1325, 10.1177/106002809302701102 · DOI
  190. Nijland, 2007, Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis, Clin Infect Dis, 45, 1001, 10.1086/521894 · DOI
  191. Aristoff, 2010, Rifamycins—obstacles and opportunities, Tuberculosis (Edinb), 90, 94, 10.1016/j.tube.2010.02.001 · DOI
  192. Baciewicz, 2013, Update on rifampin, rifabutin, and rifapentine drug interactions, Curr Med Res Opin, 29, 1, 10.1185/03007995.2012.747952 · DOI
  193. Niemi, 2003, Pharmacokinetic interactions with rifampicin: clinical relevance, Clin Pharmacokinet, 42, 819, 10.2165/00003088-200342090-00003 · DOI · Paper page
  194. Narita, 2000, Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis, Clin Infect Dis, 30, 779, 10.1086/313771 · DOI
  195. Burman, 2001, Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials, Clin Pharmacokinet, 40, 327, 10.2165/00003088-200140050-00002 · DOI · Paper page
  196. Sterling, 2011, Three months of rifapentine and isoniazid for latent tuberculosis infection, N Engl J Med, 365, 2155, 10.1056/NEJMoa1104875 · DOI · Paper page
  197. Finch, 2002, Rifampin and rifabutin drug interactions: an update, Arch Intern Med, 162, 985, 10.1001/archinte.162.9.985 · DOI
  198. Vandevelde, 1991, Rifampin and ansamycin interactions with cyclosporine after renal transplantation, Pharmacotherapy, 11, 88, 10.1002/j.1875-9114.1991.tb03603.x · DOI
  199. Lopez-Montes, 2004, Treatment of tuberculosis with rifabutin in a renal transplant recipient, Am J Kidney Dis, 44, e59, 10.1016/S0272-6386(04)00947-3 · DOI
  200. Loeliger, 2012, Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?, Int J Tuberc Lung Dis, 16, 6, 10.5588/ijtld.10.0626 · DOI

200 of 506 shown

Cited by

See all 1,170

Metadata

Authors
Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., Higashi, J. M., Ho, C. S., Hopewell, P. C., Keshavjee, S. A., Lienhardt, C., Menzies, R., Merrifield, C., Narita, M., O'Brien, R., Peloquin, C. A., Raftery, A., Saukkonen, J., Schaaf, H. S., Sotgiu, G., Starke, J. R., Migliori, G. B., & Vernon, A.
Affiliations
  • University 1     , San Francisco
  • Johns Hopkins University 2   , Baltimore, Maryland
  • 3  California Department of Public Health, Richmond
  • McMaster University 4   , Hamilton, Ontario , Canada
  • National Jewish Health 5   , Denver, Colorado
  • World Health Organization 6   , Geneva , Switzerland
  • Tuberculosis Control Section 7   , San Francisco Department of Public Health, California
  • National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention 8   Division of Tuberculosis Elimination , , Atlanta, Georgia
  • Harvard Medical School 9   , Boston, Massachusetts
  • McGill University 10   , Montreal, Quebec , Canada
  • Tuberculosis Control Program, Seattle and King County Public Health, and University of Washington 12   , Seattle
  • International Union Against TB and Lung Disease 13   Ethics Advisory Group , , Paris , France
  • University of Florida 14   , Gainesville
  • Boston University 15   , Massachusetts
  • 16  Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa
  • University of Sassari 17   , Italy
  • Baylor College of Medicine 18   , Houston, Texas
  • 11  WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri Care and Research Institute, Tradate, Italy
Venue
Clinical Infectious Diseases
Publisher
Oxford University Press (OUP)
Published
2016-08-10
Volume
63
Issue
7
Pages
e147-e195
ISSN
  • 1537-6591
  • 1058-4838
DOI
10.1093/cid/ciw376
Cited by
1,170
References
7
Language
en
Funders
  • American Thoracic Society
  • IDSA
  • CDC
  • NIH

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. https://app.cochat.ai/papers/10.1093/cid/ciw376
The paper
Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., Higashi, J. M., Ho, C. S., Hopewell, P. C., Keshavjee, S. A., Lienhardt, C., Menzies, R., Merrifield, C., Narita, M., O'Brien, R., . . . Vernon, A. (2016). Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciw376

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.